Month: June 2023

Keith Siegner Named Executive Vice President and Chief Financial Officer STAMFORD, Conn., June 07, 2023 (GLOBE NEWSWIRE) — The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World’s Most Adaptable Couch, today announced effective June 30, 2023, after six and a half years with Lovesac, Donna Dellomo is retiring as EVP and CFO and plans to take on a Senior Strategic Advisory role. In this role, Ms. Dellomo would be providing strategic, financial, operational, and organizational development insight around Company initiatives and help ensure a smooth transition of current responsibilities. The Company is also announcing the appointment of Keith Siegner as the Company’s new Executive Vice President and Chief Financial Officer effective June 30, 2023. Shawn...

STAMFORD, Conn., June 07, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12, 2023 beginning at 11:20 a.m. PT / 2:20 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference. About SpringWorks TherapeuticsSpringWorks is a clinical-stage biopharmaceutical company applying...

RYE, N. Y., June 07, 2023 (GLOBE NEWSWIRE) — Gabelli Funds will host its 15th Annual Media & Entertainment Symposium at the Harvard Club in New York City on Thursday, June 8, 2023. The symposium will feature discussions with leading companies and organizations across the media ecosystem, with an emphasis on industry dynamics, current trends, and business fundamentals, as well as a Sports Investing Panel. Attendees will also have the opportunity to meet with management in a one-on-one setting. For those who cannot attend in person, the symposium will also be available via webcast. Investors should contact their relationship person for more information, or click on the link below to register. Presenting Companies & Agenda  7:50 am Opening Remarks   Hanna Howard & Paul Fanelli, Gabelli Funds  8:00 Beasley Broadcast...

DENVER, June 07, 2023 (GLOBE NEWSWIRE) — Atlas Technical Consultants Inc. (Atlas), a leading infrastructure and environmental solutions provider, has expanded its footprint with the opening of a new hub office in Denver, Colorado. The new hub will serve as the growth and service provider for the Mountain Region. “Denver’s long-range plan for the region includes complete neighborhoods and complete transportation networks; a measured, common-sense approach to new growth; and land-use decisions through the lens of social equity,” Atlas Chief Operating Officer Ken Burns said. “This aligns with Atlas overarching goals to build sustainable and resilient communities and to offer bold, smart, innovative solutions and by staying flexible and close to our clients in economically vibrant regions like the Rocky Mountain area.” All four of...

WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023, at 9:20 a.m. PT. The event will be available via a live webcast from the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event. About Apellis Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in...

Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) — POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that it will host a virtual Investor Day on Tuesday, June 20, 2023, at 12:00 PM ET. The webcast is expected to last approximately 90 minutes. The event will include presentations by the Executive team on:POINT’s vertically integrated and highly differentiated platform for the development and commercialization of radiopharmaceuticals, highlighting the Company’s foundational investments into supply chain and manufacturing The significance and breadth of the untapped potential for radioligand therapy today and the...

Figure 1 Surface Map – Dorset Gold Trend new drilling, Golden Sky Project Location MapHighlights:Winter 2023 infill drilling program at the Dorset Zone intersected significant gold mineralization including 5.1 g/t Au over 8.0 metres within a broader zone of 2.8 g/t Au over 16.0 metres and 3.4 g/t Au over 6.0 metres within a wider interval of 2.2 g/t Au over 16.0 metres Nine (9) of the final fifteen (15) winter drill holes were completed as infill holes on the Dorset Zone resource area and all holes intersected gold mineralization The 2023 Summer drilling program focused on the Banded Iron Formation is scheduled to begin on June 8th and will test new exploration targets generated by the extensive ground geophysics programs completed earlier this yearTORONTO, June 07, 2023 (GLOBE NEWSWIRE) — Angus Gold Inc. (TSX-V: GUS | OTC:...

Research Directed by Faculty of the Center for Transplantation Sciences, Massachusetts General Hospital TNX-1500 is Expected to Enter Phase 1 Clinical Development in Third Quarter 2023 CHATHAM, N.J, June 07, 2023 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced data from two oral presentations and one poster presentation at the 2023 American Transplant Congress (ATC) by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital. The data involve studies of Tonix’s TNX-1500 (Fc-modified anti-CD40L monoclonal antibody) in development for the prevention of organ transplant rejection. The molecular target of TNX-1500 is CD40-ligand (CD40L), which is also known as CD154. Copies of the presentations are available...

GERMANTOWN, Md. and DAVIS, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and University of California, Davis (UC Davis), today announce an agreement to roll out proprietary Orgenesis Mobile Processing Units and Labs™ (“OMPULs™”) at medical or academic institutions within the University of California system. The partnership agreement sets out a staged approach through which Orgenesis will install and operate OMPULs™, enabling their proprietary point-of-care (“POCare”) Service Platform to manufacture therapeutics at hospitals throughout California, empowering onsite production for clinical trials like the cell and gene therapies in development...

Topline results from the Phase 2 trial of VTX002 (S1P1R modulator) in ulcerative colitis and the Phase 2 trial of VTX958 (TYK2 inhibitor) in plaque psoriasis are expected in Q4 2023 ENCINITAS, Calif., June 07, 2023 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 SERENITY trial of VTX958 in plaque psoriasis. “I am very proud of our team’s execution as we mark another important milestone for Ventyx and for ulcerative colitis and plaque psoriasis patients,” said Dr. William Sandborn, President and Chief Medical...